Announcements
- Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
- Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
- Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
- Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
- Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
- Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
- Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
- Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
More ▼
Key statistics
As of last trade, Cyclacel Pharmaceuticals Inc (UXI:STU) traded at 2.34, 107.08% above the 52 week low of 1.13 set on Apr 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.32 |
---|---|
High | 2.38 |
Low | 2.32 |
Bid | 1.89 |
Offer | 2.08 |
Previous close | 1.79 |
Average volume | 466.67 |
---|---|
Shares outstanding | 1.46m |
Free float | 1.36m |
P/E (TTM) | -- |
Market cap | 3.86m USD |
EPS (TTM) | -21.99 USD |
Data delayed at least 15 minutes, as of Jun 03 2024.
More ▼